< Back to news blog

Oslo University Hospital to use Ledidi for COVID-19-studies

Oslo University Hospital and Ledidi recently agreed on a contract implying that PRJCTS can be used for all COVID-19 research the hospital is involved in. This means that PRJCTS will be used in nationwide clinical research on patients with the coronavirus.


As this represents the first big contract for Ledidi, our CEO Einar Martin Aandahl is very enthusiastic: “We are so excited that PRJCTS, through this agreement, is entering the scientific world and can become useful for many researchers. This is what we dreamed of when we started developing PRJCTS – a tool for supporting and accelerating important research and make research collaboration between researchers in different institutions more fluid.”

Several studies originating from OUH has already started using PRJCTS. Among them is a study named “Norwegian SARS-CoV-2 study – Virological, clinical and immunological characterisation of inpatients during the covid-19 outbreak”, which aims at increasing the understanding of why some patients become severely ill from COVID-19, while others only get mild infections. The study origins in the departments of immunology, microbiology and acute medicine at OUH, but has developed into a multicenter study involving hospitals from all parts of Norway. PRJCTS is used for the collection of patient data from different locations and will be used in further analysis of the gathered data. The study is anticipated to provide much needed data on the course of the COVID-19 infection, as well as generating knowledge about the virus and its transmission.

“We are so eager to see what insight can come from this research!” says Aandahl.

The contract with OUH also implies that PRJCTS has been approved regarding the strict requirements for privacy and data security held by the hospital. As Norway and OUH is known for their high standards on data security, this also represents a milestone for Ledidi. “Keeping patient data safe is fundamental in all health-related research. PRJCTS would be worthless for clinical research if it did not confirm to these standards, and undoubtably security has been our top priority from day one. It is therefore very satisfactory that through this contract, the solution’s security aspects have been confirmed from competent third parties,” Aandahl proudly admits.

Aandahl is currently assisting several other research groups at OUH setting up their covid-studies in PRJCTS. “In order to combat the pandemic, it’s important to understand more of the virus. We are honored to be able to contribute to these projects,” Aandahl concludes.

The contract has also brought on attention from the media. You can read more in these articles:

Dagens medisin: Leger og forsker utviklet nytt forskningsverktøy

Digi.no: Legene fant ikke forskningsverktøyet de trengte

Finansavisen: Medtechselskap landet prestisjeavtale og toppinvestorer

Oslo cancer cluster: Accelerating cancer research with data sharing